| Literature DB >> 35855753 |
Abstract
Obesity is one of the major health-threatening conditions nowadays. Nigella sativa (NS) is a medicinal plant that demonstrates multiple therapeutic effects. In the current review, we aim to evaluate the weight lowering effect of NS in both clinical trials and experimental studies and to explore the possible reported mechanisms of this effect. We searched PubMed and Web of science and retrieved 14 clinical trials and 5 experimental studies that justify our inclusion criteria. After the analysis of these articles, we can conclude that long-term administration of NS for 6-12 weeks can significantly lower bodyweight and other anthropometric indices. NS-oil is more potent than NS-powder in lowering bodyweight probably due to the higher concentration of fatty acids and thymoquinone. The weight lowering effect of NS is not a toxic effect, it conversely and preferably lowers the elevated liver enzymes in condition of fatty liver. It is also frequently accompanied by positive metabolic modifications, such as enhancement of lipid profile, lowering blood glucose and improving insulin resistance. Possible mechanisms for NS-bodyweight lowering effect might include an appetite-suppression effect, lowering caloric-intake and inhibition of intestinal glucose absorption. However, further experimental evidence is required to support these mechanisms or unveil new ones.Entities:
Keywords: BMI; Nigella sativa; bodyweight; obesity; waist-circumference
Mesh:
Substances:
Year: 2022 PMID: 35855753 PMCID: PMC9288173 DOI: 10.2147/VHRM.S373702
Source DB: PubMed Journal: Vasc Health Risk Manag ISSN: 1176-6344
Figure 1Flow diagram for the process of article selection.
Clinical Trials That Tested the Effect of Nigella sativa (NS) on the Anthropometric Data. The Studies are Presented in a Descending Chronological Order
| # | Authors | Type of Study | Country of the Study | Population and Groups | Dose and Duration | Anthropometric Effects | Other Metabolic Effects |
|---|---|---|---|---|---|---|---|
| 1 | Safi et al 2021. | Crossover, double-blinded, randomized controlled, clinical trial | Iran | 39 women aged 25–55 years with BMI 27–35 kg/m2 | Significant reduction of BW, WC, body fat mass, body fat percent, fat-free mass, and visceral fat area | Sensation of appetite decreased significantly as assessed by a visual scale and no difference in dietary intake | |
| 2 | Mostafa et al 2021. | Open label, randomized, study, | Egypt | 117 obese prediabetic individuals | Significant reduction in TC, triglyceride, LDL, FBG, HOMA-insulin resistance, fasting insulin | ||
| 3 | Hadi et al 2021. | Double blinded controlled clinical trial | Iran | 43 patients with type 2 diabetes (23 women and 20 men; aged 53.5 ± 7.4 years) | Two 500-mg per day soft gel capsules containing | Significant reduction of BMI and WC. | Significant reduction of HbA1c, TC, triglyceride, LDL, SBP, and DBP |
| 4 | Tavakoli-Rouzbehani et al 2021. | Double-blinded, randomized, controlled clinical trial | Iran | 60 patients with coronary artery disease divided into two groups: | 2 g of | Significant reduction of BW, BMI, WC, HC W/P ratio | Significant reduction of SBP, DBP, and FBG |
| 5 | Shirazi et al 2020. | Double-blinded randomized, controlled trial | Iran | 140 menopausal women within the age of 45–60 years old, who were suffering from metabolic syndrome divided into two equal groups: | 500 mg | No significant difference in BW, and WC | Significant difference in |
| 6 | Moustafa et al 2019 | Open label randomized clinical trial | Egypt | 21 Newly diagnosed diabetic patients with age range 18–60 years and not on antidiabetic medications. | Significant reduction of BW, WC, BMI comparable to the effect of metformin | Significant reduction of FBG, fasting insulin, insulin resistance, liver enzyme: ALT, TC, LDL, HDL, triglycerides, and total antioxidant capacity but not HbA1c, and B cell secretory function, comparable to the effect of metformin | |
| 7 | Hussain et al 2017 | Randomized Controlled clinical trial | UAE & Pakistan | 70 non-alcoholic fatty liver patients, male 66–60% | 2 capsules each contains 1 g of freshly grinded | Significant reduction of BW, and BMI. | Significant reduction of liver enzymes: ALT and AST. |
| 8 | Farhangi et al 2016 | Randomized controlled study | Iran | 40 patients of Hashimoto’s thyroiditis aged 22–50 years, 85% females, divided randomly into two groups: | 2 capsules of 1 g powdered | Significant reduction of BW, BMI, WC, and HC. | Significant increase in T3, and T4, and significant reduction of TSH. VEGF, nesfatin-1 |
| 9 | Mahdavi et al 2015 | Double-blinded, randomized controlled clinical trial | Iran | 84 obese women aged 25–50 years old with BMI= 30–35 kg/m2 | Intervention: low-calorie diet with 3 g | Significant reduction in BW and WC in the | Significant decline in triglyceride and VLDL levels in the |
| 10 | Namazi et al 2015. | Double-blinded, controlled randomized clinical trial | Iran | 49 volunteer obese women, BMI = 30–35 kg/m2, aged 25–50 years. Participants were randomly divided into Group 1: Intervention n= 25 | Intervention group: low-calorie diet with 3 g/day | BW is reduced in both groups but more in the | Significant increase in superoxide dismutase (SOD) in |
| 11 | Abdul Latiff et al 2014. | Open label crossover study | Malaysia | 69 perimenopausal women aged 45–65 years divided randomly into two groups: | Treatment group:1600mg/day of encapsulated pure powdered | No significant change in body weight, waist circumference, BMI, W/H ratio. | Significant decrease in LDL only. |
| 12 | Bamosa et al 2010. | Randomized clinical trial | Saudi Arabia. | 94 uncontrolled diabetic patients | 1,2 or 3 g of grinded | No significant change in BW | A dose of 2 gm/day caused significant reductions in FBG, 2-hours postprandial glucose, insulin resistance, and HbA1c |
| 13 | Datau et al 2010. | Double-blind randomized Controlled clinical trial | Indonesia | 39 Central obese men aged 30–45 years divided randomly into two groups | Treatment: two capsules of 750 mg of grinded | Significant reduction of BW and WC in the treatment group in comparison to pre-treatment and to the control group. | |
| 14 | Qidwai et al 2009. | Randomized, double-blinded, controlled trial | Pakistan | 73 individuals aged ≥18 years, with serum total cholesterol level between >180 to <250 mg/dl or >250 mg/dl on statins for a minimum of one month divided into two groups: | 2 capsules of 500 mg crushed powdered | No significant change was found in BMI, WC, and HC. | No significant change was found in TC, LDL, HDL, triglyceride between |
Abbreviations: ALT, alanine transaminase (Liver enzyme); AST, aspartate aminotransferase (liver enzyme); BMI, body mass index; BW, body weight; DBP, diastolic blood pressure; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; HC, hip circumference; HDL, high density lipoprotein; HOMA-insulin resistance, Homeostatic Model Assessment for Insulin Resistance; LDL, low density lipoprotein; NS, Nigella sativa; SBP, systolic blood pressure; TC, total cholesterol; TNF-α, tumor necrosis factor alpha; T3, tri-iodothyronin (thyroid hormone); T4, thyroxine (thyroid hormone); TSH, thyroid stimulating hormone; VEGF, vascular endothelial growth factor; VLDL, very low density lipoprotein; WC, waist circumference; W/H, waist/Hip ratio.
Experimental Studies That Tested the Effect of Nigella sativa (NS) on Bodyweight
| Animal | Groups and Treatment | Anthropometric Findings | Other Metabolic Findings | ||
|---|---|---|---|---|---|
| 1 | Anwar et al 2021. | 40 female BALB/c mice | 4 equal groups: | Group 2: increase BW significantly compared to the other groups. | |
| 2 | Al Asoom 2017. | 40 male albino Wistar rats | 3 equal groups: | No difference in final BW or BWG among all the groups | |
| 3 | Parhizkar et al 2011. | 40 ovariectomized female Sprague Dawley rats, weighting 250–350 g | 5 equal groups: | The | Significant less LDL, HDL, and BG in |
| 4 | Meddah et al 2009. | 30 male and female (50:50) Sprague Dawley weighing 220–260 g | 3 equal groups: | BW was significantly lower in | In vivo glucose tolerance test: chronic feeding of |
| 5 | Mai Le et al 2004. | 14 Male Sprague–Dawley rats, aged 7 weeks and weighing approximately 250 g | 2 equal groups: | Final body weight and weight gain was significantly less in | Significant reduction of insulin, and triglyceride and significant increase of HDL. |
Abbreviations: AUC, area under the curve; BG, blood glucose; BW, body weight; BWG, body weight gain; HDL, high density lipoprotein; LDL, low density lipoprotein; NS, Nigella sativa; OGTT, oral glucose tolerance test.
Clinical Trials and Experimental Studies That Explore the Mechanisms of Nigella sativa (NS) Effect on Bodyweight and Anthropometric Data
| # | Study | Proposed and Tested Mechanism | Result |
|---|---|---|---|
| 1 | Mahdavi et al | Anorexic or reduce food intake | Dietary intake was changed in both groups compared to the baseline, but the difference was not significant between the two groups. |
| 2 | Farhangi et al | Anorexic or reduce food intake | No significant difference in total dietary intake for 3 days |
| 3 | Safi et al | Anorexic or reduce food intake | Sensation of appetite decreased significantly as assessed by a visual scale and no difference in dietary intake after |
| 4 | Mai Le et al | Anorexic or reduce food intake | Food intake was significantly less in |
| 5 | Meddah et al | Inhibition of intestinal glucose absorption | In vitro examination showed |
| 6 | Moustafa et al | Decrease insulin secretion | |
| 7 | Mai Le et al | Decrease insulin secretion | |
| 8 | Mahdavi et al | Increased adiponectin levels |
Notes: *The same study mentioned in Table 1. **The same study mentioned in Table 2. ¥Both articles belong to the same study.